NEONasdaqServices-Testing LaboratoriesFiscal year ends December 31
NEOGENOMICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$16.42−0.23 (-1.38%)
Close on Oct 19, 2026
- Market cap
- $2.15B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$6.37 (+63.38%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
NEOGENOMICS INC grew revenue 11.2% to $766.30M over the twelve months to Jun 30, 2026. Free cash flow was -$7.36M.
Revenue
$766.30M
+11.2% vs. a year earlier
Operating income
-$68.44M
TTM Q2 2026
Free cash flow
-$7.36M
TTM Q2 2026
EPS, diluted
-$0.40
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.15B
- P/E ratio
- –
- Price to sales
- 2.80
- Price to book
- 2.73
- Dividend yield
- –
- Free cash flow yield
- -0.34%
Fundamentals
- Revenue
- $766.30M
- Net income
- -$51.88M
- EPS, diluted
- -$0.40
- Free cash flow
- -$7.36M
- Book value per share
- $6.01
- Diluted shares
- 131M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$766.30M+11.2% YoY
Gross profit
$336.53M+11.2% YoY
Operating income
-$68.44M
Net income
-$51.88M
EPS, diluted
-$0.40
Free cash flow
-$7.36M
Reported periodTrailing twelve months